AASLD 2011 Annual Meeting
ID#1382
Locationoster Hall
Time of Presentation:Nov 07 8:00 AM - 5:30 PM Premenstrual syndrome
Relieving pms
Category:SO2. Treatment and Clinical Trials
Add -on of peg interferon to a stable Stable angina
Unstable angina
nucleoside regimen led to loss of HBs Ag in chronic [color=#006cc8 !important][color=#006cc8 !important]hepatitis HBe Ag negative patients
D. Ouzan1; G. Penaranda2; H. Joly1; H. Khiri2; P. Halfon2
1. Institut Arnault Tzanck, Saint-Laurent du Var, France.
2. Laboratoire ALPHABIO, Marseille, France.
Objectives: Suppression of HBV viral load by nucleoside treatment reduces disease progression but requires indefinite treatment. Hbs Ag loss is a rare event after long term treatment with analogues therapy. In HBe Ag negative patients peg interferon alpha Alpha fetoprotein
2a for 96 weeks improved the sustained responses rate versus 48 weeks. It is of interest to know whether the addition of peg interferon for 96 weeks to a stable nucleoside therapy will reduce quantitative HBs-Ag which may follow by HBs Ag loss.
Methods: We analyzed HBs Ag levels of 10 patients who received additional peg –interferon alpha2a as an individualized therapy during 96 weeks according to the evolution of HBsAg titer. All patients were male; HBe Ag negative; median age was 58 (range 41-76) years. Current treatments were lamivudine (one patient) adefovir (three patients), entecavir (two patients), lamivudine + adefovir (two patients), adefovir+entecavir (two patients). Median baseline HBsAg was 660 IU/ml range (50-1754). HBV DNA was below the limit of detection <20UI/ml in all patients for more than 3 years.
Results: During add-on therapy, in four patients, a continuous decline of quantitative HBs Ag lead to negative values <10 UI/ml between 24 and 48 weeks. All antiviral (peg interferon and nucleoside analogue) therapy was stopped at week 48 in these 4 patients and results remain the same 24 week after cessation of all therapy (AgHBs loss and HBV DNA negative). HBs serocoversion was observed in one out of these four patients. Quantitative HBsAg highly decreased in five of the remaining six patients. For one patient, HBsAg remained high; treatment was stopped in this patient at week 24. The remaining five patients received peg interferon for 72 week at the time of this analysis. Median decrease of quantitative HBs Ag was 834 IU/ml in these five patients (compared with a decrease of 34 IU/ml in the patient with low decrease).
Conclusions: In patients with sustained virological remission under long term nucleoside analogue therapy, add-on of peg interferon allows HBsAg loss in 40% of our patients. HBsAg titer decline constitutes a useful tool which predicts the loss of HBsAg and may lead to the optimal duration of IFN therapy.
oster Hall 
为什么表抗消失了还需要长期治疗呢？？
好好好!